Quick Answer
KALA BIO, Inc. reported Total Assets of $55.48 million for the year ending 2024.
- KALA BIO, Inc. showed a decrease of -0.8% in Total Assets from 2023 to 2024.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $28.59 million | Q3 2017: $123.69 million | Q1 2018: $104.99 million | Q2 2018: $95.59 million | Q3 2018: $84.08 million | Q1 2019: $197.02 million | Q2 2019: $178.82 million | Q3 2019: $161.01 million | Q1 2020: $258.53 million | Q2 2020: $245.51 million | Q3 2020: $225.10 million | Q1 2021: $229.83 million | Q2 2021: $215.46 million | Q3 2021: $193.81 million | Q1 2022: $111.57 million | Q2 2022: $84.98 million | Q3 2022: $85.70 million | Q1 2023: $72.23 million | Q2 2023: $66.50 million | Q3 2023: $61.12 million | Q1 2024: $53.03 million | Q2 2024: $61.61 million | Q3 2024: $54.08 million | Q4 2024: $55.48 million | Q1 2025: $48.25 million | Q2 2025: $36.05 million | Q3 2025: $25.02 million.
- Over the full 9 years of available data (2016 to 2024), KALA BIO, Inc.'s Total Assets has grown by 19.8%.
- Historical annual values: Fiscal year 2024: $55.48 million | Fiscal year 2023: $55.95 million | Fiscal year 2022: $86.82 million | Fiscal year 2021: $139.43 million | Fiscal year 2020: $221.61 million | Fiscal year 2019: $154.32 million | Fiscal year 2018: $220.97 million | Fiscal year 2017: $116.55 million | Fiscal year 2016: $46.33 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: